ANSAID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ANSAID (ANSAID).
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
| Metabolism | Hepatic metabolism via hydroxylation and glucuronidation; major metabolites are 4'-hydroxyflurbiprofen and conjugated flurbiprofen. |
| Excretion | Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts. |
| Half-life | Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged. |
| Protein binding | >99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.14-0.17 L/kg, indicating limited extravascular distribution consistent with high protein binding. |
| Bioavailability | Oral bioavailability is approximately 80-100% (rapid and complete absorption). |
| Onset of Action | Oral: Analgesic effect begins within 1-2 hours; anti-inflammatory effect may be noted within a few days but full benefit may require 1-2 weeks. |
| Duration of Action | Duration of analgesic effect is 4-6 hours. Anti-inflammatory effects persist with continued dosing; clinical response is typically seen after 1-2 weeks of therapy. |
| Action Class | NSAID's- Non-Selective COX 1&2 Inhibitors (acetic acid) |
| Brand Substitutes | Pamagin Plus Gel, Diclogen Plus Gel, Ontac Gel, Novanac Gel, Lytix D Gel |
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: reduce dose by 50%; GFR <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use. |
| Pediatric use | Not recommended for use in pediatric patients. |
| Geriatric use | Initiate at lowest effective dose (e.g., 100 mg once daily), titrate cautiously; maximum 200 mg/day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ANSAID (ANSAID).
| Breastfeeding | Not recommended; M/P ratio unknown. Excreted in breast milk in small amounts, but potential for adverse effects in neonates (e.g., platelet dysfunction, renal impairment) precludes use. |
| Teratogenic Risk | First trimester: Increased risk of cardiac malformations and gastroschisis with NSAID use. Second trimester: Avoid due to potential fetal renal dysfunction and oligohydramnios. Third trimester: Contraindicated due to risk of premature ductus arteriosus closure and persistent pulmonary hypertension. |
| Fetal Monitoring |
■ FDA Black Box Warning
Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs are contraindicated for treatment of perioperative pain in coronary artery bypass graft (CABG) surgery.
| Serious Effects |
Hypersensitivity to flurbiprofen or any NSAID; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; active gastrointestinal bleeding or ulceration; advanced renal disease; third trimester of pregnancy.
| Precautions | Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; fluid retention and edema; renal toxicity; anaphylactoid reactions; serious skin reactions (e.g., Stevens-Johnson syndrome); avoid in late pregnancy. |
| Food/Dietary | Alcohol increases risk of gastrointestinal bleeding. High-fat meals may delay absorption but do not significantly affect overall bioavailability. Avoid excessive salt intake to reduce fluid retention. |
Loading safety data…
| Monitor for oligohydramnios (perform ultrasound if prolonged use). Fetal echocardiography if used in first trimester. Assess maternal renal function and bleeding risk. |
| Fertility Effects | Reversible inhibition of prostaglandin synthesis may impair fertilization and implantation; may delay or prevent ovulation. Use not recommended in women attempting conception. |
| Clinical Pearls | ANSAID (flurbiprofen) is a nonsteroidal anti-inflammatory drug (NSAID) with potent analgesic and anti-inflammatory properties. It is often used for rheumatoid arthritis and osteoarthritis. Due to its short half-life (3-4 hours), it may require frequent dosing. Caution in elderly and renal impairment; monitor renal function. Gastrointestinal bleeding risk is significant; consider co-administration with a proton pump inhibitor in high-risk patients. Avoid use in patients with aspirin-sensitive asthma. Therapeutic effect may take up to 2 weeks. |
| Patient Advice | Take with food or milk to reduce stomach upset. · Avoid alcohol while taking this medication. · Report signs of bleeding (black stools, vomiting blood), weight gain, or edema. · Do not take with other NSAIDs or aspirin without consulting doctor. · May cause dizziness or drowsiness; avoid driving if affected. · Store at room temperature away from moisture and heat. |